Latest Period
Q2 2026
CUSIP: G9TY5A101
Latest Period
Q2 2026
Institutions Reporting
40
Shares (Excl. Options)
14,289,772
Price
$5.90
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 40 institutions filings for Q2 2026.
Security key
G9TY5A101
Latest holder period
Q2 2026
13F holders
40
13D/G owners
10
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP G9TY5A101:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 18% | -8.5% | $103,223,132 | +$28,154,420 | 19,699,071 | +38% | AI Biotechnology LLC | 26 Feb 2026 |
| Athanor Capital | 16% | 0% | $60,678,440 | 11,581,402 | 0% | Athanor Capital | 23 Jan 2026 | |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $59,192,796 | +$20,882,077 | 9,816,384 | +55% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.9% | +14% | $57,431,306 | +$23,862,290 | 9,524,263 | +71% | Suvretta Capital Management, LLC | 31 Mar 2026 |
| JPMORGAN CHASE & CO | 4.7% | -35% | $26,962,035 | -$1,212,633 | 4,471,316 | -4.3% | JPMORGAN CHASE & CO | 30 Apr 2026 |
| GREAT POINT PARTNERS LLC | 4.4% | -15% | $25,422,058 | +$2,412,000 | 4,215,930 | +10% | Great Point Partners, LLC | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | $4,633,204 | 3,217,503 | RA Capital Management, L.P. | 31 Dec 2024 | |||
| PFIZER INC | 4.6% | $4,276,832 | 2,970,022 | Pfizer Inc. 13-5315170 | 31 Dec 2024 | |||
| ADAR1 Capital Management, LLC | 3.2% | $2,991,241 | 2,077,251 | ADAR1 Capital Management, LLC | 31 Dec 2024 | |||
| Deep Track Capital, LP | 0.4% | -96% | $1,121,531 | -$18,867,975 | 259,014 | -94% | Deep Track Capital, LP | 30 Sep 2025 |
As of 30 Jun 2026, 40 institutional investors reported holding 14,289,772 shares of Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA). This represents 14% of the company’s total 99,155,394 outstanding shares.
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 9.5% | 9,443,001 | +4.1% | 1.2% | $55,713,706 |
| Venrock Adviser, LLC | 6.5% | 6,434,990 | 0% | 1.2% | $37,966,441 |
| MPM BIOIMPACT LLC | 4.5% | 4,472,843 | 1.6% | $26,389,774 | |
| JPMORGAN CHASE & CO | 4.4% | 4,354,715 | -2.3% | 0% | $24,517,046 |
| GREAT POINT PARTNERS LLC | 4.3% | 4,215,930 | 0% | 5.9% | $24,873,987 |
| BRAIDWELL LP | 4% | 3,980,295 | -0.22% | 0.87% | $23,483,741 |
| Siren, L.L.C. | 3.8% | 3,734,866 | 0% | 0.45% | $22,035,709 |
| BlackRock, Inc. | 3.6% | 3,614,695 | +690% | 0% | $21,326,701 |
| Commodore Capital LP | 3.3% | 3,250,000 | 0% | 1.1% | $19,175,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8% | 2,750,000 | 0% | 0.02% | $16,225,000 |
| Saturn V Capital Management LP | 2.1% | 2,101,119 | +184% | 1.8% | $12,396,602 |
| QVT Financial LP | 1.9% | 1,895,153 | +45% | 0.72% | $11,181,403 |
| ADAR1 Capital Management, LLC | 1.8% | 1,759,295 | +179% | 0.49% | $10,379,841 |
| ARMISTICE CAPITAL, LLC | 1.6% | 1,636,000 | +8.6% | 0.27% | $9,652,400 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,584,209 | +200% | 0% | $9,348,520 |
| Affinity Asset Advisors, LLC | 1.5% | 1,464,303 | -43% | 0.42% | $8,639,388 |
| STEMPOINT CAPITAL LP | 1.4% | 1,368,215 | +82% | 1.4% | $8,072,469 |
| Ikarian Capital, LLC | 1.2% | 1,218,492 | +2.1% | 1.2% | $7,189,102 |
| EcoR1 Capital, LLC | 1.2% | 1,179,715 | 0% | 0.35% | $6,960,319 |
| Vestal Point Capital, LP | 1.2% | 1,173,956 | +130% | 0.16% | $6,926,340 |
| STATE STREET CORP | 1% | 1,001,637 | +414% | 0% | $5,909,658 |
| Boxer Capital Management, LLC | 0.91% | 900,000 | 0% | 0.4% | $5,310,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.75% | 747,352 | +54% | 0% | $4,409,377 |
| GOLDMAN SACHS GROUP INC | 0.58% | 573,946 | +275% | 0% | $3,386,281 |
| Pfizer Inc | 0.54% | 538,841 | -81% | 1.7% | $2,882,799 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 14,289,772 | $82,839,202 | +$15,106,581 | $5.90 | 40 |
| 2026 Q1 | 66,058,173 | $391,774,465 | +$125,573,004 | $5.95 | 94 |
| 2025 Q4 | 44,873,374 | $235,135,504 | +$20,832,407 | $5.24 | 74 |
| 2025 Q3 | 41,126,986 | $178,078,060 | +$26,729,478 | $4.33 | 65 |
| 2025 Q2 | 35,347,572 | $37,112,793 | -$12,588,212 | $1.05 | 62 |
| 2025 Q1 | 45,725,666 | $58,985,346 | +$1,915,127 | $1.29 | 74 |
| 2024 Q4 | 42,890,401 | $107,244,382 | -$472,426 | $2.50 | 87 |
| 2024 Q3 | 37,204,097 | $151,039,161 | +$13,196,426 | $4.06 | 77 |
| 2024 Q2 | 32,818,331 | $114,851,034 | +$63,732,200 | $3.50 | 55 |
| 2024 Q1 | 14,795,561 | $37,551,435 | -$1,318,315 | $2.57 | 43 |
| 2023 Q4 | 15,148,165 | $70,695,884 | +$2,995,975 | $4.67 | 43 |
| 2023 Q3 | 14,140,309 | $93,326,247 | +$8,351,323 | $6.60 | 41 |
| 2023 Q2 | 12,843,918 | $105,028,129 | +$104,999,517 | $8.20 | 38 |
| 2023 Q1 | 25,742 | $24,692 | +$24,692 | $10.00 | 3 |